The CTN collaborated with the Division of Pharmacotherapies & Medical Consequences of Drug Abuse (DPMCDA) on this multi-centered trial to compare the effect of buprenorphine/naloxone (Bup/Nx) and methadone (MET) on liver function. This was a randomized, open-label, multi-center, Phase 4 study in participants entering opioid agonist treatment programs at community centers (methadone centers) throughout the country. The study randomized approximately 1,300 participants at 8 sites across 6 Nodes.
CTN Protocol ID:
CTN-0027
DSMB ID:
DSMB-0027
Status:
Completed
ClinicalTrials.gov ID:
Principal Investigator(s)
Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
United States
Participating Sites
- Bay Area Addiction Research/Treatment, California
- Matrix Institute on Addictions, California
- Northeast Treatment Centers, Delaware
- Connecticut Counseling Centers, Inc., Connecticut
- CODA, Inc., Oregon
- Evergreen Treatment Services, Washington